It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
HLA-E is a non-classical class I MHC protein involved in innate and adaptive immune recognition. While recent studies have shown HLA-E can present diverse peptides to NK cells and T cells, the HLA-E repertoire recognized by CD94/NKG2x has remained poorly defined, with only a limited number of peptide ligands identified. Here we screen a yeast-displayed peptide library in the context of HLA-E to identify 500 high-confidence unique peptides that bind both HLA-E and CD94/NKG2A or CD94/NKG2C. Utilizing the sequences identified via yeast display selections, we train prediction algorithms and identify human and cytomegalovirus (CMV) proteome-derived, HLA-E-presented peptides capable of binding and signaling through both CD94/NKG2A and CD94/NKG2C. In addition, we identify peptides which selectively activate NKG2C+ NK cells. Taken together, characterization of the HLA-E-binding peptide repertoire and identification of NK activity-modulating peptides present opportunities for studies of NK cell regulation in health and disease, in addition to vaccine and therapeutic design.
HLA-E is a highly conserved MHC-l recognized by NK and T cells. The authors characterize HLA-E-presented peptides recognized by CD94/NKG2x, identifying human and CMV-derived peptide ligands which can modulate NK cell activity when presented by HLA-E, including for selective NK cell activation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.516087.d); Department of Biological Engineering, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
2 Innate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Leibniz Institut, Berlin, Germany (GRID:grid.418217.9) (ISNI:0000 0000 9323 8675)
3 University of Oxford, Centre for Immuno-Oncology, Old Road Campus Research Building, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.516087.d); Ragon Institute of MGH, MIT, and Harvard, Cambridge, USA (GRID:grid.461656.6) (ISNI:0000 0004 0489 3491)
5 Innate Immunity, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Leibniz Institut, Berlin, Germany (GRID:grid.418217.9) (ISNI:0000 0000 9323 8675); Charité - Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
6 Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.516087.d); Department of Biological Engineering, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Ragon Institute of MGH, MIT, and Harvard, Cambridge, USA (GRID:grid.461656.6) (ISNI:0000 0004 0489 3491)